Main Article Content
Abstract
Objective
In the present study, we evaluated anti-Parkinson’s activity of Ropinirole hydrochloride loaded in microsphere by intranasal delivery for brain targeting.
Material & Method
All animal experiments were approved and performed in Malla Reddy College of Pharmacy accordance with the guidelines of Institutional Animal Ethics Committee (CPCSEA Registration No: 1217/PO/RE/S/2008).
Result
For In-Vivo evaluation of nasal microspheres of Ropinirole Hydrochloride, rabbit was chosen as a model for study because the blood volume of the rabbit is sufficiently large (approximately 300 ml) to permit frequent blood sampling and allow a full characterization of the absorption and determination of the pharmacokinetic profile of the drug. The Cmax after oral dosing was found to be 107.833±1.567 ng/ml and the corresponding Tmax was at 1.86±0.066 hrs.
Conclusion
From all the parameters studied, it can be concluded that combination of Carbopol 974P and guar gum is better mucoadhesive polymer for the formulation of mucoadhesive microspheres of Ropinirole Hydrochloride for intranasal administration. Thus, the formulated microspheres seem to be a potential candidate as intranasal controlled drug delivery system for treatment of Parkinson’s disease.
Keywords
Article Details
References
- [1]. Matheson, A.J., Spencer, C.M., Ropinirole: a review of its use in the management of Parkinson’s disease. Drugs 60, 2000, 115–137.
- [2]. Jost, W.H., Angersbach, D., Ropinirole, a non-ergoline dopamine agonist. CNS Drug Rev 11, 2005, 253–272.
- [3]. Kaye, C.M., Nicholls, B., Clinical pharmacokinetics of ropinirole. ClinPharmacokinet 39, 2000, 243–254.
- [4]. Dauer W, Przedborski S Parkinson's disease: mechanisms and models. Neuron 39, 2003, 889-909.
- [5]. Asanuma M, Miyazaki I, Diaz-Corrales FJ, Ogawa N Quinone formation as dopaminergic neuron-specific oxidative stress in the pathogenesis of sporadic Parkinson's disease and neurotoxin-induced parkinsonism. Acta Med Okayama 58, 2004, 221-233.
- [6]. Bove J, Prou D, Perier C, Przedborski S Toxin-induced models of Parkinson's disease. Neuro Rx 2, 2005, 484-494.
- [7]. Graff CL, Pollack GM P-Glycoprotein attenuates brain uptake of substrates after nasal instillation. Pharm Res 20, 2003, 1225-1230.
- [8]. Hawkes CH, Del Tredici K, Braak H Parkinson's disease: a dual-hit hypothesis. NeuropatholApplNeurobiol 33, 2007, 599-614.
- [9]. OECD. OECD Guideline for Testing of Chemicals—Acute Dermal Irritation, Corrosion, revised version, Guideline No. 404, adopted 1981.OECD, Rome, Italy.
- [10]. USFDA (2003). Guidance for Industry: Bioavailability and bioequivalence studies for orally administered drug products-General considerations. US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), Rockville, MD. Available at: www.fda.gov/cder/guidance/index.html.
References
[1]. Matheson, A.J., Spencer, C.M., Ropinirole: a review of its use in the management of Parkinson’s disease. Drugs 60, 2000, 115–137.
[2]. Jost, W.H., Angersbach, D., Ropinirole, a non-ergoline dopamine agonist. CNS Drug Rev 11, 2005, 253–272.
[3]. Kaye, C.M., Nicholls, B., Clinical pharmacokinetics of ropinirole. ClinPharmacokinet 39, 2000, 243–254.
[4]. Dauer W, Przedborski S Parkinson's disease: mechanisms and models. Neuron 39, 2003, 889-909.
[5]. Asanuma M, Miyazaki I, Diaz-Corrales FJ, Ogawa N Quinone formation as dopaminergic neuron-specific oxidative stress in the pathogenesis of sporadic Parkinson's disease and neurotoxin-induced parkinsonism. Acta Med Okayama 58, 2004, 221-233.
[6]. Bove J, Prou D, Perier C, Przedborski S Toxin-induced models of Parkinson's disease. Neuro Rx 2, 2005, 484-494.
[7]. Graff CL, Pollack GM P-Glycoprotein attenuates brain uptake of substrates after nasal instillation. Pharm Res 20, 2003, 1225-1230.
[8]. Hawkes CH, Del Tredici K, Braak H Parkinson's disease: a dual-hit hypothesis. NeuropatholApplNeurobiol 33, 2007, 599-614.
[9]. OECD. OECD Guideline for Testing of Chemicals—Acute Dermal Irritation, Corrosion, revised version, Guideline No. 404, adopted 1981.OECD, Rome, Italy.
[10]. USFDA (2003). Guidance for Industry: Bioavailability and bioequivalence studies for orally administered drug products-General considerations. US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), Rockville, MD. Available at: www.fda.gov/cder/guidance/index.html.